Lung cancer immunotherapy: progress, pitfalls, and promises
A Lahiri, A Maji, PD Potdar, N Singh, P Parikh, B Bisht… - Molecular cancer, 2023 - Springer
Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Molecular mechanism of VEGF and its role in pathological angiogenesis
Over the last seven decades, a significant scientific contribution took place in the delineation
of the implications of vascular endothelialderived growth factor (VEGF) in the processes of …
of the implications of vascular endothelialderived growth factor (VEGF) in the processes of …
[HTML][HTML] Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling
M Entezari, M Ghanbarirad, A Taheriazam… - Biomedicine & …, 2022 - Elsevier
Among the different kinds of tumors threatening human life, lung cancer is one that is
commonly observed in both males and females. The aggressive behavior of lung cancer …
commonly observed in both males and females. The aggressive behavior of lung cancer …
Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects
S Tang, C Qin, H Hu, T Liu, Y He, H Guo, H Yan… - Cells, 2022 - mdpi.com
Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …
An integrated single-cell transcriptomic dataset for non-small cell lung cancer
KH Prazanowska, SB Lim - Scientific Data, 2023 - nature.com
As single-cell RNA sequencing (scRNA-seq) has emerged as a great tool for studying
cellular heterogeneity within the past decade, the number of available scRNA-seq datasets …
cellular heterogeneity within the past decade, the number of available scRNA-seq datasets …
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
C Zhou, Z Wang, M Sun, L Cao, Z Ma, R Wu, Y Yu… - Nature cancer, 2023 - nature.com
The randomized, double-blinded, multi-center, phase III GEMSTONE-302 (NCT03789604)
study evaluated the efficacy and safety of sugemalimab versus placebo in combination with …
study evaluated the efficacy and safety of sugemalimab versus placebo in combination with …
Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer
A Grenda, E Iwan, I Chmielewska, P Krawczyk, A Giza… - AMB Express, 2022 - Springer
The significance of Akkermansia bacteria presence in gut micobiome, mainly Akkermansia
mucinifila, is currently being investigated in the context of supporting therapy and marker for …
mucinifila, is currently being investigated in the context of supporting therapy and marker for …
[HTML][HTML] Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter …
PA Zucali, CC Lin, BC Carthon, TM Bauer… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Preclinical data suggest that concurrent treatment of anti-CD38 and
antiprogrammed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies …
antiprogrammed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies …
[HTML][HTML] Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
P Vryza, T Fischer, E Mistakidi, A Zaravinos - Translational Oncology, 2023 - Elsevier
Immune checkpoint inhibition (ICI) therapies have reshaped the therapeutic landscape in
lung cancer management, providing first-time improvements in patient response, prognosis …
lung cancer management, providing first-time improvements in patient response, prognosis …
Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer
B Zuo, T Li, X Liu, S Wang, J Cheng, X Liu… - Clinical and …, 2023 - Springer
Purpose The efficacy of immune checkpoint inhibitors such as programmed cell death ligand
1 (PD-L1) antibodies in non-small cell lung cancer (NSCLC) is limited, and combined use …
1 (PD-L1) antibodies in non-small cell lung cancer (NSCLC) is limited, and combined use …